OmniAb, Inc. (Form: 4, Received: 11/03/2022 19:01:34)

FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^* Avista Acquisition GP LLC II	2. Issuer Name and Ticker or Trading Symbol OmniAb, Inc. [ OABI ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director __X__ 10% Owner _____ Officer (give title below) _____ Other (specify below)
(Last) (First) (Middle) 65 EAST 55TH STREET, 18TH FLOOR	3. Date of Earliest Transaction (MM/DD/YYYY) 11/1/2022
(Street) NEW YORK, NY 10022	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) ___ Form filed by One Reporting Person _ X _ Form filed by More than One Reporting Person
(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common stock, par value $0.0001 per share	11/1/2022		A		10,172,934 ⁽³⁾	A	$10	15,817,934 ⁽⁴⁾	I	See Notes ⁽¹⁾⁽²⁾

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)
Warrants	$11.5	11/1/2022		A		11,345,489 ⁽⁵⁾⁽⁶⁾		⁽⁵⁾⁽⁶⁾	11/1/2027	Common stock, par value $0.0001	11,345,489	⁽⁵⁾⁽⁶⁾	11,345,489	I	See Notes ⁽¹⁾⁽²⁾

Explanation of Responses:
(1)	This form is being filed by each of the following Reporting Persons: Avista Acquisition LP II, a Cayman Islands limited partnership ("Avista Sponsor"), Avista Acquisition GP LLC II, a Cayman Islands limited liability company ("Avista GP"), which is the general partner of Avista, and Thompson Dean and David Burgstahler, who are the managers of Avista GP. Because of the relationships among the Reporting Persons, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any.
(2)	Directly owned by Avista Sponsor.
(3)	Avista Sponsor acquired the shares of common stock of OmniAb, Inc. (f/k/a Avista Public Acquisition Corp. II) (the "Issuer") in accordance with the Agreement and Plan of Merger, dated as of March 23, 2022 (the "Merger Agreement"), by and among the Issuer, Ligand Pharmaceuticals Incorporated, OmniAb, Inc. ("Legacy OmbiAb"), and Orwell Merger Sub Inc. and the Amended and Restated Forward Purchase Agreement, dated March 23, 2022, by and among the Issuer, Avista Sponsor and Legacy OmniAb (the "A&R Forward Purchase Agreement").
(4)	In accordance with the letter agreement, dated March 23, 2022, among the Issuer, Avista Sponsor, Legacy OmniAb and other parties (the "Letter Agreement"), if the Triggering Event (as defined in the Letter Agreement) has not occurred during the Earnout Period (as defined in the Letter Agreement), 1,293,299 shares of common stock will be automatically forfeited to the Issuer for no consideration.
(5)	In connection with the completion of the Issuer's August 2021 initial public offering, Avista Sponsor purchased 8,233,333 warrants in a private placement from the Issuer, each exercisable to purchase (subject, initially, to the satisfaction of certain material conditions) one Class A ordinary share, par value $0.0001 per share, of the Issuer for $11.50 per share. The material conditions to exercise were satisfied upon the closing of the transactions contemplated by the Merger Agreement (the "Closing"), and the warrants by their terms become exercisable (including by cash settlement) 30 days following the Closing.
(6)	In connection with the A&R Forward Purchase Agreement, Avista Sponsor purchased an aggregate 3,112,156 warrants in private placements from the Issuer, each exercisable to purchase (subject, initially, to the satisfaction of certain material conditions) one share of common stock, par value $0.0001 per share, of the Issuer for $11.50 per share. The material conditions to exercise were satisfied on the Closing, and the warrants by their terms become exercisable (including by cash settlement) 30 days following the Closing.

Remarks:
In accordance with the Merger Agreement, the Issuer, a then Cayman Islands exempted company, domesticated as a Delaware corporation (the "Domestication") and subsequently changed its name to "OmniAb, Inc." Pursuant to the Domestication, the 5,645,000 Class B ordinary shares of the Issuer, par value $0.0001 per share, directly owned by Avista Sponsor, converted automatically, on a one-for-one basis, into 5,645,000 shares of common stock, par value $0.0001 per share, of the Issuer. Exhibit 24.1 (Power of Attorney) and Exhibit 99.1 (Joint Filer Information and Signatures) are hereby incorporated by reference herein.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Avista Acquisition GP LLC II 65 EAST 55TH STREET 18TH FLOOR NEW YORK, NY 10022	X	X
Burgstahler David F 65 EAST 55TH STREET 18TH FLOOR NEW YORK, NY 10022	X	X
Dean Thompson 65 EAST 55TH STREET 18TH FLOOR NEW YORK, NY 10022	X	X
Avista Acquisition LP II 65 EAST 55TH STREET 18TH FLOOR NEW YORK, NY 10022	X	X

Signatures
See Exhibit 99.1		11/3/2022
^**Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Exhibit 24.1

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints Benjamin Silbert with full power of substitution, the undersigned’s true and lawful attorney-in-fact to:

execute for and on behalf of the undersigned with respect to OmniAb, Inc. (the “Company”), Schedules 13D and 13G and Forms 3, 4, and 5 in accordance with Sections 13 and 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;

do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Schedules 13D or 13G or Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority; and

take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

The undersigned hereby grant to the attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledge that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming any of the undersigned’s responsibilities to comply with Sections 13 and 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned’s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact.

[Signature Page Follows]

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 3rd day of November, 2022.

	Avista Acquisition LP II

	By: Avista Acquisition GP LLC II, its general partner

	/s/ David Burgstahler
	Name:	David Burgstahler
	Title:	Manager

	Avista Acquisition GP LLC II

	/s/ Thompson Dean
	Name:	Thompson Dean
	Title:	Manager

	Thompson Dean

	/s/ Thompson Dean
	Name:	Thompson Dean

	David Burgstahler

	/s/ David Burgstahler
	Name:	David Burgstahler

[Signature Page to Power of Attorney]

Exhibit 99.1

Joint Filer Information

Name of Joint Filer:	Avista Acquisition LP II

Address of Joint Filer:	65 East 55th Street, 18th Floor
	New York, NY 10022

Relationship of Joint Filer to Issuer:	10% Owner, Director

Issuer Name and Ticker or Trading Symbol:	OmniAb,Inc. [OABI]

Date of Earliest Transaction Required to be Reported (Month/Day/Year):	November 1, 2022

Designated Filer:	Avista Acquisition GP LLC II

Signature:

Avista Acquisition LP II

/s/ Benjamin Silbert
Name:	Benjamin Silbert
Title:	Attorney-in-fact

Dated: November 3, 2022

Joint Filer Information

(continued)

Name of Joint Filer:	Avista Acquisition GP LLC II

Address of Joint Filer:	65 East 55th Street, 18th Floor
	New York, NY 10022

Relationship of Joint Filer to Issuer:	10% Owner, Director

Issuer Name and Ticker or Trading Symbol:	OmniAb,Inc. [OABI]

Date of Earliest Transaction Required to be Reported (Month/Day/Year):	November 1, 2022

Designated Filer:	Avista Acquisition GP LLC II

Signature:

Avista Acquisition GP LLC II

/s/ Benjamin Silbert
Name:	Benjamin Silbert
Title:	Attorney-in-fact

Dated: November 3, 2022

Joint Filer Information

(continued)

Name of Joint Filer:	Thompson Dean

Address of Joint Filer:	65 East 55th Street, 18th Floor
	New York, NY 10022

Relationship of Joint Filer to Issuer:	10% Owner, Director

Issuer Name and Ticker or Trading Symbol:	OmniAb,Inc. [OABI]

Date of Earliest Transaction Required to be Reported (Month/Day/Year):	November 1, 2022

Designated Filer:	Avista Acquisition GP LLC II

Signature:

By:	/s/ Benjamin Silbert
	Name: Benjamin Silbert, Attorney-in-Fact for Thompson Dean

Dated: November 3, 2022

Joint Filer Information

(continued)

Name of Joint Filer:	David Burgstahler

Address of Joint Filer:	65 East 55th Street, 18th Floor
	New York, NY 10022

Relationship of Joint Filer to Issuer:	10% Owner, Director

Issuer Name and Ticker or Trading Symbol:	OmniAb,Inc. [OABI]

Date of Earliest Transaction Required to be Reported (Month/Day/Year):	November 1, 2022

Designated Filer:	Avista Acquisition GP LLC II

Signature:

By:	/s/ Benjamin Silbert
	Name: Benjamin Silbert, Attorney-in-Fact for David Burgstahler

Dated: November 3, 2022